Want to join the conversation?
$CELG's sales from Pomalyst/Imnovid for 3Q15 jumped by 41.6% from last year, reflecting net sales of $150.1MM in the U.S. and $106.4MM in international markets. Increases in market share and treatment duration contributed to the increase in U.S. and international net sales of Pomalyst/Imnovid.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.